These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 10669150)

  • 1. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.
    van Baal WM; Emeis JJ; van der Mooren MJ; Kessel H; Kenemans P; Stehouwer CD
    Thromb Haemost; 2000 Jan; 83(1):29-34. PubMed ID: 10669150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women.
    van Baal WM; Kenemans P; van der Mooren MJ; Kessel H; Emeis JJ; Stehouwer CD
    Thromb Haemost; 1999 Jun; 81(6):925-8. PubMed ID: 10404769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
    Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
    Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thrombophilic syndrome associated to phenotypic resistance to activated protein C in postmenopausal women].
    Caserta L; Caserta R; Torella M; Perricone F; Nesti E; Sessa M; Tagliaferri A; De Francesco F; De Lucia D; Panariello S
    Minerva Ginecol; 2004 Apr; 56(2):131-6. PubMed ID: 15258541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
    Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
    Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
    Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hemostatic balance during treatment with the newest contraceptives].
    Petersen KR; Skouby SO; Sidelmann J; Jespersen J
    Ugeskr Laeger; 1994 Jan; 156(2):187-90. PubMed ID: 8296409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
    Vogelvang TE; Mijatovic V; Kenemans P; Emeis JJ; Heijst JA; van der Mooren MJ
    Am J Obstet Gynecol; 2005 Oct; 193(4):1384-94. PubMed ID: 16202731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study.
    Thromb Haemost; 1996 Mar; 75(3):476-80. PubMed ID: 8701411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women.
    Rios DR; Rodrigues ET; Cardoso AP; Montes MB; Franceschini SA; Toloi MR
    Nutrition; 2008 Feb; 24(2):120-6. PubMed ID: 18065202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study.
    Sidelmann JJ; Jespersen J; Andersen LF; Skouby SO;
    BJOG; 2003 Jun; 110(6):541-7. PubMed ID: 12798469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women.
    Basurto L; Saucedo R; Zárate A; Martínez C; Gaminio E; Reyes E; Hernandez M
    Gynecol Obstet Invest; 2006; 61(2):61-4. PubMed ID: 16192735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
    Junge W; El-Samalouti V; Gerlinger C; Schaefers M
    Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of 17 beta-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus.
    Brussaard HE; Leuven JA; Krans HM; Kluft C
    Vascul Pharmacol; 2002 Aug; 39(3):141-7. PubMed ID: 12616982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.
    Sgarabotto M; Baldini M; Dei Cas A; Manotti C; Luciana Barilli A; Rinaldi M; Benassi L; Bacchi Modena A
    Thromb Res; 2007; 119(1):85-91. PubMed ID: 16499954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone.
    Norris LA; Brosnan J; Bonnar J; Conard J; Kluft C; Hellgren M
    Thromb Haemost; 2008 Aug; 100(2):253-60. PubMed ID: 18690345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.
    Post MS; van der Mooren MJ; van Baal WM; Blankenstein MA; Merkus HM; Kroeks MV; Franke HR; Kenemans P; Stehouwer CD
    Am J Obstet Gynecol; 2003 Nov; 189(5):1221-7. PubMed ID: 14634544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
    Hemelaar M; van der Mooren MJ; Mijatovic V; Bouman AA; Schijf CP; Kroeks MV; Franke HR; Kenemans P
    Menopause; 2003; 10(6):550-8. PubMed ID: 14627865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.